Iodixanol
Iodixanol, Visipaque (iodixanol) is an unknown pharmaceutical. Iodixanol was first approved as Visipaque 270 on 1996-03-22.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Iodixanol, Visipaque (discontinued: Visipaque)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iodixanol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VISIPAQUE 270 | GE Healthcare | N-020351 RX | 1996-03-22 | 1 products, RLD, RS |
| VISIPAQUE 320 | GE Healthcare | N-020351 RX | 1996-03-22 | 1 products, RLD, RS |
| VISIPAQUE 320 | GE Healthcare | N-020808 RX | 1997-08-29 | 1 products |
Show 1 discontinued
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | — | — | 2 | 6 | 5 | 13 |
| Renal insufficiency | D051437 | — | N19 | — | — | 1 | 10 | 1 | 12 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 6 | 2 | 8 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | 4 | 3 | 8 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 2 | 2 | 4 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | — | — | 2 | 2 | 4 |
| Embolism | D004617 | — | — | — | — | — | 2 | 2 | 4 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | 2 | 3 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | 1 | 2 | 3 |
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | 1 | — | 3 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | — | N17 | 1 | — | 1 | — | 1 | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | 1 | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | — | 1 |
| Carotid stenosis | D016893 | — | — | — | — | 1 | — | — | 1 |
| Computed tomography angiography | D000072226 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 2 | 2 |
| Cardio-renal syndrome | D059347 | — | — | — | — | — | — | 2 | 2 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 2 | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 1 | 1 |
| Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
| Mesothelioma | D008654 | — | C45 | — | — | — | — | 1 | 1 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
| St elevation myocardial infarction | D000072657 | — | — | — | — | — | — | 1 | 1 |
Show 17 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Iodixanol |
| INN | iodixanol |
| Description | Iodixanol is a dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography. It has a role as a radioopaque medium. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I |
Identifiers
| PDB | — |
| CAS-ID | 92339-11-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200507 |
| ChEBI ID | 31705 |
| PubChem CID | 3724 |
| DrugBank | DB01249 |
| UNII ID | HW8W27HTXX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,844 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bl-c kit, Iodixanol, Visipaque
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,010 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use